sur Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Sets Course for Human Trials with Avance Clinical Agreement
Onco-Innovations Limited announced a Start-Up Agreement with Avance Clinical Pty Ltd to facilitate clinical trials for its Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This contract will aid in preparing essential regulatory documents needed for human testing. The collaboration focuses on advanced-stage cancers with PTEN1 or SHP-12 deficiencies.
Avance will offer regulatory and clinical expertise, developing key materials such as an Investigator's Brochure and a detailed clinical trial protocol. A nonclinical gap analysis by Avance will assess any remaining preclinical work, with plans for a pre-IND meeting with the FDA aimed at aligning trial design and reducing risks.
Onco's CEO, Thomas O'Shaughnessy, emphasized the significance of turning scientific research into clinical opportunities through this partnership.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Onco-Innovations Limited